Chitosan as a novel nasal delivery system for vaccines

被引:547
作者
Illum, L [1 ]
Jabbal-Gill, I [1 ]
Hinchcliffe, M [1 ]
Fisher, AN [1 ]
Davis, SS [1 ]
机构
[1] Drug Delivery & Clin Res Ctr Ltd, W Pharmaceut Serv, Albert Einstein Ctr, Nottingham NG7 2TN, England
关键词
chitosan; nasal vaccines; diphtheria; influenza; pertussis; phase I clinical study; DNA delivery;
D O I
10.1016/S0169-409X(01)00171-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A variety of different types of nasal vaccine systems has been described to include cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus and cells and outer membrane proteins (proteosomes). The present review describes our work on the use of the cationic polysaccharide, chitosan as a delivery system for nasally administered vaccines. Several animal studies have been carried out on influenza, pertussis and diphtheria vaccines with good results. After nasal administration of the chitosan-antigen nasal vaccines it was generally found that the nasal formulation induced significant serum IgG responses similar to and secretory IgA levels superior to what was induced by a parenteral administration of the vaccine. Animals vaccinated via the nasal route with the various chitosan-antigen vaccines were also found to be protected against the appropriate challenge. So far the nasal chitosan vaccine delivery system has been tested for vaccination against influenza in human subjects. The results of the study showed that the nasal chitosan influenza vaccine was both effective and protective according to the CPMP requirements. The mechanism of action of the chitosan nasal vaccine delivery system is also discussed. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:81 / 96
页数:16
相关论文
共 29 条
  • [1] Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens
    Bacon, A
    Makin, J
    Sizer, PJ
    Jabbal-Gill, I
    Hinchcliffe, M
    Illum, L
    Chatfield, S
    Roberts, M
    [J]. INFECTION AND IMMUNITY, 2000, 68 (10) : 5764 - 5770
  • [2] The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
    Belshe, RB
    Mendelman, PM
    Treanor, J
    King, J
    Gruber, WC
    Piedra, P
    Bernstein, DI
    Hayden, FG
    Kotloff, K
    Zangwill, K
    Iacuzio, D
    Wolff, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1405 - 1412
  • [3] Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults
    Boyce, TG
    Hsu, HH
    Sannella, EC
    Coleman-Dockery, SD
    Baylis, E
    Zhu, YW
    Barchfeld, O
    DiFrancesco, A
    Paranandi, M
    Culley, B
    Neuzil, KM
    Wright, PF
    [J]. VACCINE, 2000, 19 (2-3) : 217 - 226
  • [4] Chitosan and chitosan ethylene oxide propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines
    Calvo, P
    RemunanLopez, C
    VilaJato, JL
    Alonso, MJ
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (10) : 1431 - 1436
  • [5] Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides
    Cano, F
    Plotnicky-Gilquin, H
    Nguyen, TN
    Liljeqvist, S
    Samuelson, P
    Bonnefoy, JY
    Ståhl, S
    Robert, A
    [J]. VACCINE, 2000, 18 (24) : 2743 - 2752
  • [6] *CPMP GUID, 1997, CPMPBWP21496
  • [7] Effect of chitosan on epithelial permeability and structure
    Dodane, V
    Khan, MA
    Merwin, JR
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (01) : 21 - 32
  • [8] FitzGerald D, 2000, CRIT REV THER DRUG, V17, P165
  • [9] FRIEKE KC, 1992, IMMUNOL TODAY, V13, P219
  • [10] Illum L, 2000, STP PHARMA SCI, V10, P89